NS5B HCV RNA polymerase nucleoside inhibitors (Aviragen Therapeutics)

N/A

Report date: 2025/03/20 10:05:57
NME

Base Information

Drug NameNS5B HCV RNA polymerase nucleoside inhibitors (Aviragen Therapeutics)
Drug Alias NameHCV therapeutics (Biota/Boehringer Ingelheim)NS5B HCV RNA polymerase nucleoside inhibitors (Biota/Boehringer Ingelheim)antiviral nucleoside-based compounds (Biota/GSK)HCV therapeutics (Biota/GSK)antiviral nucleoside-based compounds (Biota) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New ZealandGermany +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiota Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiota Holdings LtdBiota IncGlaxosmithkline Plc +[5] 
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A